-
Mashup Score: 16
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated three new clinical studies evaluating Moderna’s investigational individualized neoantigen therapy in combination with Merck’s Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma Advanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor event CAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2024. “As we anticipate the launches of our Spikevax 2024-2025 formula and RSV vaccine, we are exercising financial discipline and have intensified our focus on building and
Source: investors.modernatx.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 12Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine - 1 month(s) ago
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083 CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company’s next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3
Source: investors.modernatx.comCategories: General Medicine News, Infectious DiseaseTweet-
Moderna reports promising findings for next-generation COVID vaccine “The new version offers longer shelf-life advantages and paves the way for a flu-COVID combo vaccine.” https://t.co/03SeF2IlIT
-
-
Mashup Score: 23Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19 - 7 month(s) ago
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19 mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin Phase 3 trial of mRNA-1083 in…
Source: investors.modernatx.comCategories: Hematologists1, Latest HeadlinesTweet-
RT @SukunaBikona7: https://t.co/WInKP0KPqg 2025年頃の承認を目標としていると。 インフルエンザとCOVID-19のワクチンが1回の接種で済むなら便利。
-
-
Mashup Score: 2
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Companies plan to initiate a Phase 3 study…
Source: investors.modernatx.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Moderna and Merck data update on melanoma. #asco23 https://t.co/6LW1hGWkKN
-
-
Mashup Score: 5
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in…
Source: investors.modernatx.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to go to #AACR23 this weekend, major advances @AACR in the immunotherapy oricess. Adjuvant + vaccine vs Neoadjuvant discussion heats up Jeff Weber @nyulangone @Merck @moderna_tx #Melanoma data @angelesclinic @MarkFariesMD Follow for more... https://t.co/58LAkmdBv9 https://t.co/3XOxm7D1hA
-
-
Mashup Score: 14
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval CAMBRIDGE, MA, ACCESSWIRE / January 17, 2023 / Moderna, Inc. (Nasdaq:MRNA), a…
Source: investors.modernatx.comCategories: Infectious Disease, Latest HeadlinesTweet-
Respiratory syncytial virus (RSV) vaccines are on the near horizon. Safe/effective RSV vaccines are sorely needed - this virus disproportionately impacts the very young & old. Press release from Moderna's Phase 3 trial (some real data would be nice): https://t.co/hNqqrUwoBm https://t.co/Pnhe6Y9hNu
-
-
Mashup Score: 0
In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273 Results build upon data recently published in the New England Journal of Medicine that confirmed superiority of the Company’s BA.1 bivalent vaccine, mRNA-1273.214, neutralizing titers against multiple Omicron variants compared…
Source: investors.modernatx.comCategories: Hem/Oncs, Latest HeadlinesTweet-
“As published in NEJM, a 50 µg booster dose of mRNA-1273.214 elicited a superior neutralizing antibody response against Omicron BA.1 & Omicron BA.4/BA.5 compared to the booster dose of mRNA-1273, with superiority lasting through at least three months.“ https://t.co/QZu22PPXLc
-
-
Mashup Score: 1
Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24 Company reiterates advance purchase agreements for expected delivery in 2022 of approximately $21 billion Company announces new $3 billion share repurchase plan Company has four infectious disease vaccines in Phase 3 and expects data from proof-of-concept studies in rare diseases and…
Source: investors.modernatx.comCategories: Hem/Oncs, Latest HeadlinesTweet-
So @moderna_tx raked in $4.7 Billion https://t.co/oIg0HT1jhA And With Moderna mRNA induced Myocarditis Now @moderna_tx Wants to create an mRNA injection to fix Myocarditis?! And that dear Sleepy heads is called…in @pfizer language… A “Durable Revenue Stream” @dramerling
-
-
Mashup Score: 48Bivalent COVID Booster Ph 2/3 Interim Analysis - 2 year(s) ago
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.At Moderna, we promise to treat your data…
Source: investors.modernatx.comCategories: Infectious Disease, Latest HeadlinesTweet-
That's why I *will* be getting my bivalent booster when my immune system is ready to learn more about SARS-CoV-2 in a few months. These data from Moderna show a significant benefit vs both omicron & the ancestral virus in terms of neutralizing antibodies. https://t.co/oACM6C6Leq https://t.co/0OAYq3pG2C
-
-
Mashup Score: 10Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older - 2 year(s) ago
Moderna’s Bivalent Booster Shots to be Available Nationwide In Coming Days mRNA-1273.222 Targets BA.4/.5 Strains of Omicron Variant CAMBRIDGE, MA / ACCESSWIRE / August 31, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug…
Source: investors.modernatx.comCategories: Infectious Disease, Latest HeadlinesTweet-
.@moderna_tx receives @US_FDA authorization for EUA of Omicron-targeting bivalent COVID-19 booster vaccine for adults 18 years and older. https://t.co/uGrNe21taR
-
$MRNA -- revenue down 91% in Q1 as Covid vaccine sales go pffffft. They're going to need some pipeline wins. https://t.co/LlDM8dHwye